Cansinobio (6185)
Posted: Mon May 25, 2020 1:07 pm
not vested
<Research Report>M Stanley Hikes CANSINOBIO-B (06185.HK) TP to $258; Rated Overweight
CANSINOBIO-B (06185.HK) published the first-in-human trial results of a COVID-19 vaccine (Ad5-nCoV) on the Lancet on May 22, saying the vaccine was tolerated in general.
50-75% of subjects had four times higher neutralizing antibodies, Morgan Stanley reported.
CANSINOBIO-B was kept at Overweight, with target ramped up from $102 to $258.
The base-case success rate for vaccine development was 60%.
The broker also expected the vaccine to be approved in late 2020 or early 2021, with a sales volume of 80 million doses next year at RMB30-100 each.
Source: AAStocks Financial News
<Research Report>M Stanley Hikes CANSINOBIO-B (06185.HK) TP to $258; Rated Overweight
CANSINOBIO-B (06185.HK) published the first-in-human trial results of a COVID-19 vaccine (Ad5-nCoV) on the Lancet on May 22, saying the vaccine was tolerated in general.
50-75% of subjects had four times higher neutralizing antibodies, Morgan Stanley reported.
CANSINOBIO-B was kept at Overweight, with target ramped up from $102 to $258.
The base-case success rate for vaccine development was 60%.
The broker also expected the vaccine to be approved in late 2020 or early 2021, with a sales volume of 80 million doses next year at RMB30-100 each.
Source: AAStocks Financial News